Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Urokinase in Acute Myocardial Infarction: Results of the German Activator Urokinase Study (GAUS)

Autor: Neuhaus, Karl-Ludwig, Tebbe, Ulrich, Gottwik, Martin, Weber, Michael A.J., Feuerer, Werner, Niederer, Walter, Haerer, Winfried, Praetorius, Frank, Grosser, Klaus-Dieter, Huhmann, Wolfgang, Hoepp, Hans-Wilhelm, Alber, Guenter, Sheikhzadeh, Abdohlhamid, Schneider, Berthold
Zdroj: Journal of the American College of Cardiology; January 1988, Vol. 12 Issue: 3 p581-587, 7p
Abstrakt: The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency and early reocclusion of infarct-related coronary arteries were investigated in a single blind, randomized multicenter trial in 246 patients with acute myocardial infarction of < 6 h duration. Both 70 mg of single chain rt-PA with an initial bolus of 10 mg and 3 million units of urokinase with an initial bolus of 1.5 million units were given intravenously over 90 min. The first angiographic study at the end of the infusion revealed a patent infarct-related artery (Thrombolysis in Myocardial Infarction trial [TIMI] grade 2 or 3) in 69.4% of 121 patients given rt-PA versus 65.8% of 117 patients given urokinase (p = NS). Among patients treated within 3 h from symptom onset a patent infarct-related artery was found in 63.9% of 72 patients given rt-PA versus 70% of 70 patients given urokinase (p = NS).
Databáze: Supplemental Index